Gilead Sciences Inc.


Gilead To Acquire Stake in Cancer Drug Developer Pionyr For $275 Million

Gilead Sciences Inc. (GILD) announced on Tuesday that it will buy a 49.

Gilead Aims To Produce More Than 2 Million Remdesivir Courses By Year-End

Gilead Sciences Inc. (GILD) said it expects to produce more than 2 million treatment courses of its experimental coronavirus drug candidate remdesivir by …

Gilead’s Remdesivir Most ‘Beneficial’ In Covid-19 Patients Who Need Extra Oxygen, Study Shows

Gilead Sciences Inc.’s (GILD) remdesivir, its coronavirus drug candidate, is most “beneficial” for Covid-19 patients who require supplemental oxygen but don’t need mechanical …

Gilead Signs Remdesivir Licensing Agreements With Five Drugmakers

Gilead Sciences Inc.’s (GILD) signed non-exclusive licensing agreements with five generic pharmaceutical manufacturers that will allow them to produce and sell its experimental …

Gilead Shares Rise On Early Peek At Positive Covid-19 Vaccine Data

Gilead Sciences (GILD) shares popped over 16% in after-hours trading on Thursday following encouraging anecdotal data from Gilead’s remdesivir COVID-19 trials. News source …

Gilead’s Experimental Coronavirus Drug Shows “Hopeful” Signs in Small Group

The majority of a small group of coronavirus patients showed their condition improve after treatment with remdesivir, an experimental drug being developed by …

Gilead Sciences, Second Genome in Pact For Inflammatory Disease Drug Finds

Gilead Sciences Inc. (GILD) and Second Genome have entered into a four-year partnership aimed at joining forces in biomarker research and discovery of …

Gilead Sciences Expects Coronavirus Drug Data in Coming Weeks, Expands Access

Gilead Sciences Inc. (GILD) said it is expecting to have initial remdesivir drug data in coming weeks.

J.P. Morgan Weighs in on Sangamo Therapeutics Inc’s (SGMO) Collaboration with Kite

Sangamo Therapeutics Inc (NASDAQ:SGMO) has just announced a strategic collaboration with Gilead Sciences, Inc’s (NASDAQ:GILD) company Kite, and shares are putting together a massive …

Gilead Sciences, Inc. (GILD) Obtains CFDA Approval for Sovaldi for Treatment of Chronic Hepatitis C Virus Infection

Gilead Sciences, Inc. (NASDAQ:GILD) announced that the China Food and Drug Administration (CFDA) has approved Sovaldi® (sofosbuvir 400mg), a once-daily oral nucleotide analog polymerase …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts